Idarucizumab for the treatment of dabigatran-related nephropathy

Anticoagulant-related nephropathy (ARN) is a clinical syndrome of acute kidney injury in patients taking vitamin K antagonists or direct oral anticoagulants. It is associated with increased mortality and there is no specific treatment. We report the case of a 78-year-old man on dabigatran who develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsamarrai, Ammar, Eaddy, Nicola, Curry, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Exceptional Cases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894941/
https://www.ncbi.nlm.nih.gov/pubmed/35261760
http://dx.doi.org/10.1093/ckj/sfaa030
_version_ 1784662801731551232
author Alsamarrai, Ammar
Eaddy, Nicola
Curry, Elizabeth
author_facet Alsamarrai, Ammar
Eaddy, Nicola
Curry, Elizabeth
author_sort Alsamarrai, Ammar
collection PubMed
description Anticoagulant-related nephropathy (ARN) is a clinical syndrome of acute kidney injury in patients taking vitamin K antagonists or direct oral anticoagulants. It is associated with increased mortality and there is no specific treatment. We report the case of a 78-year-old man on dabigatran who developed macroscopic haematuria and acute kidney injury 2 weeks after mitral valve repair, reaching a peak creatinine of 415 µmol/L from a normal baseline, which was successfully treated with one course of idarucizumab. This case illustrates the efficacy of an anticoagulant reversal agent for the treatment of ARN.
format Online
Article
Text
id pubmed-8894941
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-88949412022-03-07 Idarucizumab for the treatment of dabigatran-related nephropathy Alsamarrai, Ammar Eaddy, Nicola Curry, Elizabeth Clin Kidney J Exceptional Cases Anticoagulant-related nephropathy (ARN) is a clinical syndrome of acute kidney injury in patients taking vitamin K antagonists or direct oral anticoagulants. It is associated with increased mortality and there is no specific treatment. We report the case of a 78-year-old man on dabigatran who developed macroscopic haematuria and acute kidney injury 2 weeks after mitral valve repair, reaching a peak creatinine of 415 µmol/L from a normal baseline, which was successfully treated with one course of idarucizumab. This case illustrates the efficacy of an anticoagulant reversal agent for the treatment of ARN. Oxford University Press 2020-03-11 /pmc/articles/PMC8894941/ /pubmed/35261760 http://dx.doi.org/10.1093/ckj/sfaa030 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Exceptional Cases
Alsamarrai, Ammar
Eaddy, Nicola
Curry, Elizabeth
Idarucizumab for the treatment of dabigatran-related nephropathy
title Idarucizumab for the treatment of dabigatran-related nephropathy
title_full Idarucizumab for the treatment of dabigatran-related nephropathy
title_fullStr Idarucizumab for the treatment of dabigatran-related nephropathy
title_full_unstemmed Idarucizumab for the treatment of dabigatran-related nephropathy
title_short Idarucizumab for the treatment of dabigatran-related nephropathy
title_sort idarucizumab for the treatment of dabigatran-related nephropathy
topic Exceptional Cases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894941/
https://www.ncbi.nlm.nih.gov/pubmed/35261760
http://dx.doi.org/10.1093/ckj/sfaa030
work_keys_str_mv AT alsamarraiammar idarucizumabforthetreatmentofdabigatranrelatednephropathy
AT eaddynicola idarucizumabforthetreatmentofdabigatranrelatednephropathy
AT curryelizabeth idarucizumabforthetreatmentofdabigatranrelatednephropathy

Ejemplares similares